Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Work In Process (2019 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Work In Process for 7 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • Quarterly Work In Process rose 60.82% to $4.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Sep 2025, up 60.82% year-over-year, with the annual reading at $2.8 million for FY2024, 80.03% up from the prior year.
  • Work In Process for Q3 2025 was $4.5 million at Xtant Medical Holdings, up from $3.4 million in the prior quarter.
  • The five-year high for Work In Process was $4.5 million in Q3 2025, with the low at $571000.0 in Q4 2021.
  • Average Work In Process over 5 years is $1.8 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Work In Process plummeted 67.05% in 2021, then skyrocketed 95.74% in 2023.
  • Over 5 years, Work In Process stood at $571000.0 in 2021, then surged by 39.75% to $798000.0 in 2022, then surged by 95.74% to $1.6 million in 2023, then skyrocketed by 80.03% to $2.8 million in 2024, then skyrocketed by 61.27% to $4.5 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $4.5 million, $3.4 million, and $3.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.